Коронавирусная болезнь 2019 (COVID-19)

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Полный текст  Аннотация

2. World Health Organization. Clinical management of COVID-19: interim guidance. 2020 [internet publication].Полный текст

3. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020 [internet publication].Полный текст

4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Полный текст  Аннотация

5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Полный текст  Аннотация

6. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Полный текст  Аннотация

7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Полный текст  Аннотация

8. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19 [Epub ahead of print].Полный текст  Аннотация

9. ENT UK. Loss of sense of smell as marker of COVID-19 infection. 2020 [internet publication].Полный текст

10. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020 Feb 5 [Epub ahead of print].Полный текст  Аннотация

11. Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 2020 Feb 5 [Epub ahead of print].Полный текст  Аннотация

12. Wang XF, Yuan J, Zheng YJ, et al. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen [in Chinese]. Zhonghua Er Ke Za Zhi. 2020 Feb 17;58(0):E008. Аннотация

13. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Полный текст  Аннотация

14. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Полный текст  Аннотация

15. Colaneri M, Sacchi P, Zuccaro V, et al. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 2020 Apr;25(16).Полный текст  Аннотация

16. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Полный текст  Аннотация

17. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Полный текст  Аннотация

18. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2020 Sep 25 [Epub ahead of print].Полный текст  Аннотация

19. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Полный текст  Аннотация

20. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Полный текст  Аннотация

21. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Полный текст  Аннотация

22. Brambilla I, Castagnoli R, Caimmi S, et al. COVID-19 in the pediatric population admitted to a tertiary referral hospital in Northern Italy: preliminary clinical data. Pediatr Infect Dis J. 2020 Jul;39(7):e160.Полный текст  Аннотация

23. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020 Apr 14;323(14):1335.Полный текст  Аннотация

24. Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020 Apr 8 [Epub ahead of print].Полный текст  Аннотация

25. American Academy of Pediatrics. Children and COVID-19: state-level data report. 2020 [internet publication].Полный текст

26. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020 Aug 27;370:m3249.Полный текст  Аннотация

27. Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. Clin Infect Dis. 2020 May 11 [Epub ahead of print].Полный текст  Аннотация

28. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Полный текст  Аннотация

29. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Полный текст  Аннотация

30. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020 Jun 8;369:m2107.Полный текст  Аннотация

31. Centers for Disease Control and Prevention. Data on COVID-19 during pregnancy. 2020 [internet publication].Полный текст

32. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Полный текст  Аннотация

33. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Полный текст  Аннотация

34. Chou R, Dana T, Buckley DI, et al. Update alert 6: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2020 Nov 24 [Epub ahead of print].Полный текст  Аннотация

35. Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis. J Hosp Infect. 2020 Nov 16 [Epub ahead of print].Полный текст  Аннотация

36. World Health Organization. Prevention, identification and management of health worker infection in the context of COVID-19. 2020 [internet publication].Полный текст

37. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19: United States, February 12 –April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-81.Полный текст  Аннотация

38. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in healthcare workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2020 Sep 1 [Epub ahead of print].Полный текст  Аннотация

39. Sahu AK, Amrithanand VT, Mathew R, et al. COVID-19 in health care workers: a systematic review and meta-analysis. Am J Emerg Med. 2020 Jun 6;38(9):1727-31.Полный текст  Аннотация

40. Shah ASV, Wood R, Gribben C, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ. 2020 Oct 28;371:m3582.Полный текст  Аннотация

41. Kambhampati AK, O'Halloran AC, Whitaker M, et al. COVID-19-associated hospitalizations among health care personnel: COVID-NET, 13 states, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1576-83.Полный текст  Аннотация

42. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Полный текст  Аннотация

43. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Полный текст  Аннотация

44. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Полный текст  Аннотация

45. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Review. 2020 Mar 3 [Epub ahead of print].Полный текст

46. Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020 Aug 29;396(10251):603-11.Полный текст  Аннотация

47. World Health Organization. SARS-CoV-2 mink-associated variant strain: Denmark. 2020 [internet publication].Полный текст

48. Statens Serum Institut. Mutations in the mink virus. 2020 [internet publication].Полный текст

49. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Полный текст  Аннотация

50. Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020 Jan 29;79:104212. Аннотация

51. Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020 Apr;92(4):433-40.Полный текст  Аннотация

52. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020 Apr 6;30(7):1346-51.Полный текст  Аннотация

53. Lam TT, Shum MH, Zhu HC, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020 Jul;583(7815):282-5.Полный текст  Аннотация

54. Mallapaty S. Animal source of the coronavirus continues to elude scientists. Nature. 2020 May 18 [Epub ahead of print].Полный текст  Аннотация

55. Oreshkova N, Molenaar RJ, Vreman S, et al. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro Surveill. 2020 Jun;25(23):32553059.Полный текст  Аннотация

56. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. 2020 [internet publication].Полный текст

57. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2020 Sep 17 [Epub ahead of print].Полный текст  Аннотация

58. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions – scientific brief. 2020 [internet publication].Полный текст

59. Centers for Disease Control and Prevention. How COVID-19 spreads. 2020 [internet publication].Полный текст

60. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564-7.Полный текст  Аннотация

61. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7).Полный текст  Аннотация

62. Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London. Clin Infect Dis. 2020 Jul 8 [Epub ahead of print].Полный текст  Аннотация

63. Colaneri M, Seminari E, Novati S, et al. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clin Microbiol Infect. 2020 Aug;26(8):1094.e1-5.Полный текст  Аннотация

64. Colaneri M, Seminari E, Piralla A, et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. J Hosp Infect. 2020 Mar 19;105(3):474-6.Полный текст  Аннотация

65. van Doorn AS, Meijer B, Frampton CMA, et al. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther. 2020 Aug 27 [Epub ahead of print].Полный текст  Аннотация

66. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Dec;9(1):386-9.Полный текст  Аннотация

67. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-3.Полный текст  Аннотация

68. Centre for Evidence-Based Medicine; Ferner RE, Murray PI, Aronson JK. Spreading SARS-CoV-2 through ocular fluids. 2020 [internet publication].Полный текст

69. Sun T, Guan J. Novel coronavirus and central nervous system. Eur J Neurol. 2020 Mar 26 [Epub ahead of print].Полный текст  Аннотация

70. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology. 2020 Jul;127(7):977-9.Полный текст  Аннотация

71. Farina A, Uccello G, Spreafico M, et al. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med. 2020 Jun;76:100-1.Полный текст  Аннотация

72. Algarroba GN, Rekawek P, Vahanian SA, et al. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. Am J Obstet Gynecol. 2020 Aug;223(2):275-8.Полный текст  Аннотация

73. Li D, Jin M, Bao P, et al. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Netw Open. 2020 May 1;3(5):e208292.Полный текст  Аннотация

74. Mei F, Bonifazi M, Menzo S, et al. First detection of SARS-CoV-2 by real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay in pleural fluid. Chest. 2020 Oct;158(4):e143-6.Полный текст  Аннотация

75. Kashi AH, De la Rosette J, Amini E, et al. Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies. Urol J. 2020 Sep 5 [Epub ahead of print].Полный текст  Аннотация

76. Frazier KM, Hooper JE, Mostafa HH, et al. SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery. JAMA Otolaryngol Head Neck Surg. 2020 Jul 23;146(10):964-6.Полный текст  Аннотация

77. Yan Y, Diao B, Liu Y, et al. Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein in the ocular tissues of a patient previously infected with coronavirus disease 2019. JAMA Ophthalmol. 2020 Oct 8 [Epub ahead of print].Полный текст  Аннотация

78. Bwire GM, Njiro BJ, Mwakawanga DL, et al. Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: a living systematic review. J Med Virol. 2020 Oct 22 [Epub ahead of print].Полный текст  Аннотация

79. Walker KF, O'Donoghue K, Grace N, et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. BJOG. 2020 Oct;127(11):1324-36.Полный текст  Аннотация

80. Groß R, Conzelmann C, Müller JA, et al. Detection of SARS-CoV-2 in human breastmilk. Lancet. 2020 Jun 6;395(10239):1757-8.Полный текст  Аннотация

81. Tam PCK, Ly KM, Kernich ML, et al. Detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breast milk of a mildly symptomatic patient with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020 May 30 [Epub ahead of print].Полный текст  Аннотация

82. Costa S, Posteraro B, Marchetti S, et al. Excretion of SARS-CoV-2 in human breast milk. Clin Microbiol Infect. 2020 Oct;26(10):1430-2.Полный текст  Аннотация

83. Salvatore CM, Han JY, Acker KP, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study. Lancet Child Adolesc Health. 2020 Oct;4(10):721-7.Полный текст  Аннотация

84. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Полный текст  Аннотация

85. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. 2020 [internet publication].Полный текст

86. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Полный текст  Аннотация

87. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Полный текст  Аннотация

88. Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. 2020 [internet publication].Полный текст

89. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang province, China, 2020. Emerg Infect Dis. 2020 May 17;26(5).Полный текст  Аннотация

90. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Полный текст  Аннотация

91. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Полный текст  Аннотация

92. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2020 Mar 19 [Epub ahead of print].Полный текст  Аннотация

93. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Полный текст  Аннотация

94. Du Z, Xu X, Wu Y, et al. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020 Mar 19;26(6).Полный текст  Аннотация

95. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic transmission of SARS-CoV-2: Singapore, January 23 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):411-5.Полный текст  Аннотация

96. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Полный текст  Аннотация

97. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Полный текст  Аннотация

98. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. Ann Intern Med. 2020 Aug 13 [Epub ahead of print].Полный текст  Аннотация

99. World Health Organization. Advice on the use of masks in the context of COVID-19: interim guidance. 2020 [internet publication].Полный текст

100. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Полный текст  Аннотация

101. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Полный текст  Аннотация

102. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Полный текст  Аннотация

103. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Полный текст  Аннотация

104. He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020 Jul 21 [Epub ahead of print].Полный текст  Аннотация

105. Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. Int J Infect Dis. 2020 Jul 2;98:372-80.Полный текст  Аннотация

106. Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10).Полный текст  Аннотация

107. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 2020 Mar 23;368:m1165.Полный текст  Аннотация

108. Centre for Evidence-Based Medicine; Heneghan C, Brassey J, Jefferson T. COVID-19: What proportion are asymptomatic? 2020 [internet publication].Полный текст

109. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020 Sep 1;173(5):362-7.Полный текст  Аннотация

110. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility: King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-81.Полный текст  Аннотация

111. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 May 28;382(22):2081-90.Полный текст  Аннотация

112. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020 Sep;17(9):e1003346.Полный текст  Аннотация

113. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients – Nashville, Tennessee. Clin Infect Dis. 2020 Jul 6 [Epub ahead of print].Полный текст  Аннотация

114. Vahidy FS, Bernard DW, Boom ML, et al. Prevalence of SARS-CoV-2 infection among asymptomatic health care workers in the Greater Houston, Texas, area. JAMA Netw Open. 2020 Jul 1;3(7):e2016451.Полный текст  Аннотация

115. Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Jun;20(6):689-96.Полный текст  Аннотация

116. Zheng B, Wang H, Yu C. An increasing public health burden arising from children infected with SARS-CoV2: a systematic review and meta-analysis. Pediatr Pulmonol. 2020 Dec;55(12):3487-96.Полный текст  Аннотация

117. Milani GP, Bottino I, Rocchi A, et al. Frequency of children vs adults carrying severe acute respiratory syndrome coronavirus 2 asymptomatically. JAMA Pediatr. 2020 Sep 14 [Epub ahead of print].Полный текст  Аннотация

118. Frieden TR, Lee CT. Identifying and interrupting superspreading events: implications for control of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020 Jun;26(6):1059-66.Полный текст  Аннотация

119. Schwartz NG, Moorman AC, Makaretz A, et al. Adolescent with COVID-19 as the source of an outbreak at a 3-week family gathering: four states, June–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 9;69(40):1457-59.Полный текст  Аннотация

120. Atrubin D, Wiese M, Bohinc B. An outbreak of COVID-19 associated with a recreational hockey game: Florida, June 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1492-3.Полный текст  Аннотация

121. Pray IW, Gibbons-Burgener SN, Rosenberg AZ, et al. COVID-19 outbreak at an overnight summer school retreat: Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1600-4.Полный текст  Аннотация

122. Ali H, Kondapally K, Pordell P, et al. COVID-19 outbreak in an Amish community: Ohio, May 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1671-4.Полный текст  Аннотация

123. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Полный текст  Аннотация

124. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships: worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-52.Полный текст  Аннотация

125. Yang H, Thompson JR. Fighting covid-19 outbreaks in prisons. BMJ. 2020 Apr 2;369:m1362.Полный текст  Аннотация

126. Rogers JH, Link AC, McCulloch D, et al. Characteristics of COVID-19 in homeless shelters: a community-based surveillance study. Ann Intern Med. 2020 Sep 15 [Epub ahead of print].Полный текст  Аннотация

127. Centre for Evidence-Based Medicine; Durand-Moreau Q, Adisesh A, Mackenzie G, et al. What explains the high rate of SARS-CoV-2 transmission in meat and poultry facilities? 2020 [internet publication].Полный текст

128. Donahue M, Sreenivasan N, Stover D, et al. Notes from the field: characteristics of meat processing facility workers with confirmed SARS-CoV-2 infection – Nebraska, April-May 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1020-2.Полный текст  Аннотация

129. Steinberg J, Kennedy ED, Basler C, et al. COVID-19 outbreak among employees at a meat processing facility: South Dakota, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 7;69(31):1015-9.Полный текст  Аннотация

130. Erfani P, Uppal N, Lee CH, et al. COVID-19 testing and cases in immigration detention centers, April-August 2020. JAMA. 2020 Oct 29 [Epub ahead of print].Полный текст  Аннотация

131. Kennedy BS, Richeson RP, Houde AJ. Risk factors for SARS-CoV-2 in a statewide correctional system. N Engl J Med. 2020 Nov 24 [Epub ahead of print].Полный текст

132. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Полный текст  Аннотация

133. Leeb RT, Price S, Sliwa S, et al. COVID-19 trends among school-aged children: United States, March 1–September 19, 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1410-5.Полный текст  Аннотация

134. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Полный текст  Аннотация

135. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Полный текст  Аннотация

136. McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020 Aug 16;10(8):e039652.Полный текст  Аннотация

137. Wassie GT, Azene AG, Bantie GM, et al. Incubation period of SARS-CoV-2: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2020 Oct 11:100607.Полный текст  Аннотация

138. Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13;27(2).Полный текст  Аннотация

139. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Полный текст  Аннотация

140. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PLoS One. 2020 Nov 11;15(11):e0242128.Полный текст  Аннотация

141. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2020 [internet publication].Полный текст

142. Inglesby TV. Public health measures and the reproduction number of SARS-CoV-2. JAMA. 2020 Jun 2;323(21):2186-7.Полный текст  Аннотация

143. Hussein M, Toraih E, Elshazli R, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Ann Surg. 2020 Nov 17 [Epub ahead of print]. Аннотация

144. Koh WC, Naing L, Chaw L, et al. What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One. 2020 Oct 8;15(10):e0240205.Полный текст  Аннотация

145. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 6;69(9):245-6.Полный текст  Аннотация

146. Cheng HY, Jian SW, Liu DP, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 Sep 1;180(9):1156-63.Полный текст  Аннотация

147. Zhang W, Cheng W, Luo L, et al. Secondary transmission of coronavirus disease from presymptomatic persons, China. Emerg Infect Dis. 2020 May 26;26(8).Полный текст  Аннотация

148. Yung CF, Kam KQ, Chong CY, et al. Household transmission of severe acute respiratory syndrome coronavirus 2 from adults to children. J Pediatr. 2020 Oct;225:249-51.Полный текст  Аннотация

149. Macartney K, Quinn HE, Pillsbury AJ, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child Adolesc Health. 2020 Nov;4(11):807-16.Полный текст  Аннотация

150. Cevik M, Tate M, Lloyd O, et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2020 Nov 19 [Epub ahead of print].Полный текст

151. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Полный текст  Аннотация

152. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020 Jul 28;71(15):799-806.Полный текст  Аннотация

153. Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020 Oct 23;371:m3862.Полный текст  Аннотация

154. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8.Полный текст  Аннотация

155. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Полный текст  Аннотация

156. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Аннотация

157. Piplani S, Singh PK, Winkler DA, et al; arXiv. In silico comparison of spike protein-ACE2 binding affinities across species; significance for the possible origin of the SARS-CoV-2 virus. 2020 [internet publication].Полный текст

158. Hanff TC, Harhay MO, Brown TS, et al. Is there an association between COVID-19 mortality and the renin-angiotensin system: a call for epidemiologic investigations. Clin Infect Dis. 2020 Jul 28;71(15):870-4.Полный текст  Аннотация

159. Wu Z, Hu R, Zhang C, et al. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care. 2020 Jun 5;24(1):290.Полный текст  Аннотация

160. Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Apr;14(2):185-92.Полный текст  Аннотация

161. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020 May 20;323(23):2427-9.Полный текст  Аннотация

162. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Полный текст  Аннотация

163. Bunyavanich S, Grant C, Vicencio A. Racial/ethnic variation in nasal gene expression of transmembrane serine protease 2 (TMPRSS2). JAMA. 2020 Sep 10;324(15):1-2.Полный текст  Аннотация

164. Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020 May 4;77(2):198-209.Полный текст  Аннотация

165. Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA. 2020 May 21;323(24):2518-20.Полный текст  Аннотация

166. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 Sep 1;173(5):350-61.Полный текст  Аннотация

167. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-8.Полный текст  Аннотация

168. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020 Jul;8(7):681-6.Полный текст  Аннотация

169. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020 Oct;20(10):1135-40.Полный текст  Аннотация

170. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med. 2020 Sep 3;383(10):989-92.Полный текст  Аннотация

171. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Nov;19(11):919-29.Полный текст  Аннотация

172. Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020 Jul 27 [Epub ahead of print].Полный текст  Аннотация

173. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health. 2020 Oct;4(10):790-4.Полный текст  Аннотация

174. Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020 Nov;1(7):e290-9.Полный текст  Аннотация

175. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Oct;1(6):e245-53.Полный текст  Аннотация

176. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020 May 11;9(5): E1417.Полный текст  Аннотация

177. Tibiriçá E, De Lorenzo A. Increased severity of COVID-19 in people with obesity: are we overlooking plausible biological mechanisms? Obesity (Silver Spring). 2020 Aug;28(8):1374.Полный текст  Аннотация

178. Bermejo-Martin JF, Almansa R, Torres A, et al. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020 Aug 1;116(10):e132-3.Полный текст  Аннотация

179. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020 Aug;7(8):e575-82.Полный текст  Аннотация

180. Maier CL, Truong AD, Auld SC, et al. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet. 2020 Jun 6;395(10239):1758-9.Полный текст  Аннотация

181. van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020 Jul 24;324(7):1-11.Полный текст  Аннотация

182. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Полный текст  Аннотация

183. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 [internet publication].Полный текст

184. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): contact tracing. 2020 [internet publication].Полный текст

185. Pringle JC, Leikauskas J, Ransom-Kelley S, et al. COVID-19 in a correctional facility employee following multiple brief exposures to persons with COVID-19: Vermont, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1569-70.Полный текст  Аннотация

186. Shen N, Zhu Y, Wang X, et al. Characteristics and diagnosis rate of 5,630 subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan, China. JCI Insight. 2020 May 21;5(10):e137662.Полный текст  Аннотация

187. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Полный текст  Аннотация

188. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): older adults. 2020 [internet publication].Полный текст

189. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people who are at higher risk for severe illness. 2020 [internet publication].Полный текст

190. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Полный текст  Аннотация

191. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Полный текст  Аннотация

192. Iacobucci G. Covid-19: Nearly half of care homes in northeast England have had an outbreak. BMJ. 2020 May 20;369:m2041.Полный текст  Аннотация

193. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Полный текст  Аннотация

194. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Полный текст  Аннотация

195. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. 2020 Aug;31(8):1040-5.Полный текст  Аннотация

196. Zeng F, Dai C, Cai P, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020 May 8 [Epub ahead of print].Полный текст  Аннотация

197. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020 Aug 19 [Epub ahead of print].Полный текст

198. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Nov 12 [Epub ahead of print].Полный текст  Аннотация

199. Hull SA, Williams C, Ashworth M, et al. Prevalence of suspected COVID-19 infection in patients from ethnic minority populations: a cross-sectional study in primary care. Br J Gen Pract. 2020 Oct 1;70(699):e696-704.Полный текст  Аннотация

200. Alaa AM, Qian Z, Rashbass J, et al. Ethnicity and outcomes of COVID-19 patients in England. 2020 [internet publication].Полный текст

201. Harrison EM, Docherty AB, Barr B, et al; SSRN. Ethnicity and outcomes from COVID-19: the ISARIC CCP-UK prospective observational cohort study of hospitalised patients. 2020 [internet publication].Полный текст

202. Centers for Disease Control and Prevention. COVIDView: a weekly surveillance summary of US COVID-19 activity. 2020 [internet publication].Полный текст

203. Yehia BR, Winegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020 Aug 3;3(8):e2018039.Полный текст  Аннотация

204. Kabarriti R, Brodin NP, Maron MI, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. JAMA Netw Open. 2020 Sep 1;3(9):e2019795.Полный текст  Аннотация

205. Rodriguez F, Solomon N, de Lemos JA, et al. Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. Circulation. 2020 Nov 17 [Epub ahead of print].Полный текст  Аннотация

206. Wortham JM, Lee JT, Althomsons S, et al. Characteristics of persons who died with COVID-19: United States, February 12 – May 18, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):923-9.Полный текст  Аннотация

207. Gold JAW, Rossen LM, Ahmad FB, et al. Race, ethnicity, and age trends in persons who died from COVID-19: United States, May–August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-21.Полный текст  Аннотация

208. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2020 Nov 12 [Epub ahead of print].Полный текст  Аннотация

209. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Полный текст  Аннотация

210. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. 2020 [internet publication].Полный текст

211. Mahumud RA, Kamara JK, Renzaho AMN. The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis. Infection. 2020 Aug 19;1-21.Полный текст  Аннотация

212. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance: United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-65.Полный текст  Аннотация

213. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Полный текст  Аннотация

214. CDC COVID-19 Response Team. Coronavirus disease 2019 in children: United States, February 12 - April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-6.Полный текст  Аннотация

215. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Полный текст  Аннотация

216. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis. 2020 Nov 20 [Epub ahead of print].Полный текст  Аннотация

217. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Полный текст  Аннотация

218. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Curr Probl Cardiol. 2020 Apr 28:100617.Полный текст  Аннотация

219. Yonas E, Alwi I, Pranata R, et al. Effect of heart failure on the outcome of COVID-19: a meta analysis and systematic review. Am J Emerg Med. 2020 Jul 9 [Epub ahead of print].Полный текст  Аннотация

220. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Полный текст  Аннотация

221. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Полный текст  Аннотация

222. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 Nov;21(11):e13128.Полный текст  Аннотация

223. Du Y, Lv Y, Zha W, et al. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2020 Sep 16:154373.Полный текст  Аннотация

224. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020 Aug 12 [Epub ahead of print].Полный текст  Аннотация

225. Hendren NS, de Lemos JA, Ayers C, et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2020 Nov 17 [Epub ahead of print].Полный текст  Аннотация

226. Savasi VM, Parisi F, Patanè L, et al. Clinical findings and disease severity in hospitalized pregnant women with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020 Aug;136(2):252-8.Полный текст  Аннотация

227. Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr. 2020 Jun 3:e202430.Полный текст  Аннотация

228. Hussain S, Baxi H, Chand Jamali M, et al. Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence. Diabetes Metab Syndr. 2020 Aug 20;14(6):1595-602.Полный текст  Аннотация

229. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020 Apr 17;14(4):395-403.Полный текст  Аннотация

230. Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. Diabetes Care. 2020 Aug 26 [Epub ahead of print].Полный текст  Аннотация

231. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-22.Полный текст  Аннотация

232. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March–July 2020. Diabetes Care. 2020 Oct 23 [Epub ahead of print].Полный текст  Аннотация

233. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Полный текст  Аннотация

234. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Полный текст  Аннотация

235. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Полный текст  Аннотация

236. Agarwal S, Schechter C, Southern W, et al. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. Diabetes Care. 2020 Oct;43(10):2339-44.Полный текст  Аннотация

237. Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care. 2020 Oct;43(10):2345-8.Полный текст  Аннотация

238. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: a meta-analysis of observational studies. Diabetes Obes Metab. 2020 Sep 1 [Epub ahead of print].Полный текст  Аннотация

239. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020 May 29 [Epub ahead of print].Полный текст  Аннотация

240. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Полный текст  Аннотация

241. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Полный текст  Аннотация

242. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Полный текст

243. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020 Jun;167:105941.Полный текст  Аннотация

244. Wang Y, Chen J, Chen W, et al. Does asthma increase the mortality of patients with COVID-19? A systematic review and meta-analysis. Int Arch Allergy Immunol. 2020 Sep 22;:1-7.Полный текст  Аннотация

245. Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 hospitalizations: an overestimated risk factor? Ann Am Thorac Soc. 2020 Aug 31 [Epub ahead of print].Полный текст  Аннотация

246. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Jun 18 [Epub ahead of print].Полный текст  Аннотация

247. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Полный текст  Аннотация

248. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Полный текст  Аннотация

249. Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int J Cancer. 2020 Jul 19 [Epub ahead of print].Полный текст  Аннотация

250. Ofori-Asenso R, Ogundipe O, Agyeman AA, et al. Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. Ecancermedicalscience. 2020 May 18;14:1047.Полный текст  Аннотация

251. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 May 29;21(7):893-903.Полный текст  Аннотация

252. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol. 2020 Jun;6:799-808.Полный текст  Аннотация

253. Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020 Jul 28;14(5):1431-7.Полный текст  Аннотация

254. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020 Oct 28 [Epub ahead of print].Полный текст  Аннотация

255. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020 Oct 6;141:92-104.Полный текст  Аннотация

256. Park R, Lee SA, Kim SY, et al. Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol. 2020 Nov 2;:1-7.Полный текст  Аннотация

257. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Полный текст  Аннотация

258. Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020 Sep 2;139:43-50.Полный текст  Аннотация

259. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Полный текст  Аннотация

260. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Полный текст  Аннотация

261. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Полный текст  Аннотация

262. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020 Jul;20(7):1800-8.Полный текст  Аннотация

263. Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020 Jun;77(6):748-54.Полный текст  Аннотация

264. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-7.Полный текст  Аннотация

265. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol. 2020 Jun;31(6):1150-6.Полный текст  Аннотация

266. Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020 Jun;97(6):1076-82.Полный текст  Аннотация

267. Latif F, Farr MA, Clerkin KJ, et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiol. 2020 May 13 [Epub ahead of print].Полный текст  Аннотация

268. Fraser J, Mousley J, Testro A, et al. Clinical presentation, treatment, and mortality rate in liver transplant recipients with coronavirus disease 2019: a systematic review and quantitative analysis. Transplant Proc. 2020 Nov;52(9):2676-83.Полный текст  Аннотация

269. Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2020 Aug 4 [Epub ahead of print].Полный текст  Аннотация

270. Salah HM, Sharma T, Mehta J. Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms. Cureus. 2020 Oct 7;12(10):e10837.Полный текст  Аннотация

271. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Полный текст  Аннотация

272. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication].Полный текст

273. Zhang J, Wang H, Wei M, et al. Incidence of cerebrovascular disease as a comorbidity in patients with COVID-19: a meta-analysis. Aging (Albany NY). 2020 Nov 23;12.Полный текст  Аннотация

274. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Полный текст  Аннотация

275. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2020 Aug 8 [Epub ahead of print].Полный текст  Аннотация

276. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Полный текст

277. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Полный текст  Аннотация

278. Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Nov;73(5):1063-71.Полный текст  Аннотация

279. Pan L, Huang P, Xie X, et al. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2020 Sep 17 [Epub ahead of print].Полный текст  Аннотация

280. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Полный текст  Аннотация

281. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Полный текст  Аннотация

282. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Полный текст  Аннотация

283. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Полный текст  Аннотация

284. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Полный текст  Аннотация

285. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Полный текст  Аннотация

286. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2020 Oct 20 [Epub ahead of print].Полный текст  Аннотация

287. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Полный текст  Аннотация

288. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2020 Oct 24 [Epub ahead of print].Полный текст  Аннотация

289. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

290. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Полный текст  Аннотация

291. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2020 Nov 19 [Epub ahead of print].Полный текст  Аннотация

292. Meltzer DO, Best TJ, Zhang H, et al. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open. 2020 Sep 1;3(9):e2019722.Полный текст  Аннотация

293. Lau FH, Majumder R, Torabi R, et al; medRxiv. Vitamin D insufficiency is prevalent in severe COVID-19. 2020 [internet publication].Полный текст

294. Rhodes JM, Subramanian S, Laird E, et al. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther. 2020 Jun;51(12):1434-7.Полный текст  Аннотация

295. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? Med Drug Discov. 2020 Apr 29:100041.Полный текст  Аннотация

296. Israel A, Cicurel A, Feldhamer I, et al; medRxiv. The link between vitamin D deficiency and Covid-19 in a large population. 2020 [internet publication].Полный текст

297. Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020 Jul 23 [Epub ahead of print].Полный текст  Аннотация

298. Pereira M, Dantas Damascena A, Galvão Azevedo LM, et al. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2020 Nov 4;1-9. Аннотация

299. Maghbooli Z, Sahraian MA, Ebrahimi M, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One. 2020 Sep 25;15(9):e0239799.Полный текст  Аннотация

300. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Полный текст

301. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: A systematic review. Environ Res. 2020 Aug 24;191:110129.Полный текст  Аннотация

302. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Полный текст  Аннотация

303. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Полный текст  Аннотация

304. Wu X, Nethery RC, Sabath BM, et al; medRxiv. Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study. 2020 [internet publication].Полный текст

305. Sajadi MM, Habibzadeh P, Vintzileos A, et al. Temperature, humidity, and latitude analysis to estimate potential spread and seasonality of coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020 Jun 1;3(6):e2011834.Полный текст  Аннотация

306. Centre for Evidence-Based Medicine; Spencer EA, Brassey J, Jefferson T, et al. Environmental weather conditions and influence on transmission of SARS-CoV-2. 2020 [internet publication].Полный текст

307. Mecenas P, Bastos RTDRM, Vallinoto ACR, et al. Effects of temperature and humidity on the spread of COVID-19: a systematic review. PLoS One. 2020;15(9):e0238339.Полный текст  Аннотация

308. Yao Y, Pan J, Liu Z, et al. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020 May 7;55(5):2000517.Полный текст  Аннотация

309. Baker RE, Yang W, Vecchi GA, et al. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science. 2020 Jul 17;369(6501):315-9.Полный текст  Аннотация

310. Sehra ST, Salciccioli JD, Wiebe DJ, et al. Maximum daily temperature, precipitation, ultra-violet light and rates of transmission of SARS-Cov-2 in the United States. Clin Infect Dis. 2020 May 30 [Epub ahead of print].Полный текст  Аннотация

311. Centre for Evidence-Based Medicine; Heneghan C, Jefferson T. Effect of latitude on COVID-19. 2020 [internet publication].Полный текст

312. Whittemore PB. COVID-19 fatalities, latitude, sunlight, and vitamin D. Am J Infect Control. 2020 Sep;48(9):1042-4.Полный текст  Аннотация

313. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Полный текст  Аннотация

314. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Полный текст  Аннотация

315. Mackey K, Kansagara D, Vela K. Update alert 5: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2020 Oct 27 [Epub ahead of print].Полный текст  Аннотация

316. Chan CK, Huang YS, Liao HW, et al. Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection infection: a systematic review and meta-analysis. Hypertension. 2020 Nov;76(5):1563-71.Полный текст  Аннотация

317. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503-11.Полный текст  Аннотация

318. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19. 2020 [internet publication].Полный текст

319. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020 [internet publication].Полный текст

320. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [internet publication].Полный текст

321. British Cardiovascular Society; British Society for Heart Failure. BSH & BCS joint statement on ACEi or ARB in relation to COVID-19. 2020 [internet publication].Полный текст

322. Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020 Aug 1;14(5):1463-5.Полный текст  Аннотация

323. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Полный текст  Аннотация

324. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol. 2020 Nov 1;134:153-5.Полный текст  Аннотация

325. Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020 Aug 4;32(2):176-87.Полный текст  Аннотация

326. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020 Oct;115(10):1707-15.Полный текст  Аннотация

327. Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2020 Jul 30 [Epub ahead of print].Полный текст  Аннотация

328. Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2020 Oct 20 [Epub ahead of print].Полный текст  Аннотация

329. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020 Nov 10 [Epub ahead of print].Полный текст  Аннотация

330. Costenaro P, Minotti C, Barbieri E, et al. SARS-CoV-2 infection in people living with HIV: a systematic review. Rev Med Virol. 2020 Sep 1:e2155.Полный текст  Аннотация

331. Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020 Oct 6;173(7):536-41.Полный текст  Аннотация

332. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2020 Oct 21 [Epub ahead of print].Полный текст  Аннотация

333. Golinelli D, Boetto E, Maietti E, et al. The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. PLoS One. 2020 Sep 18;15(9):e0239508.Полный текст  Аннотация

334. Ray JG, Schull MJ, Vermeulen MJ, et al. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study. Ann Intern Med. 2020 Nov 24 [Epub ahead of print].Полный текст  Аннотация

335. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Полный текст  Аннотация

336. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Полный текст  Аннотация

337. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020 Jun 4 [Epub ahead of print]. Аннотация

338. World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance. 2020 [internet publication].Полный текст

339. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ. 2020 Jun 10;369:m2195.Полный текст  Аннотация

340. Centre for Evidence-Based Medicine; Greenhalgh T, Chan XH, Khunti K, et al. What is the efficacy of standard face masks compared to respirator masks in preventing COVID-type respiratory illnesses in primary care staff? 2020 [internet publication].Полный текст

341. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Полный текст  Аннотация

342. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2020 [internet publication].Полный текст

343. Centers for Disease Control and Prevention. How to protect yourself and others. 2020 [internet publication].Полный текст

344. Centre for Evidence-Based Medicine; Heneghan C, Jefferson T. COVID-19 evidence is lacking for 2 meter distancing. 2020 [internet publication].Полный текст

345. Feng S, Shen C, Xia N, et al. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med. 2020 May;8(5):434-6.Полный текст  Аннотация

346. World Health Organization. Advice on the use of masks for children in the community in the context of COVID-19. 2020 [internet publication].Полный текст

347. Mahase E. Covid-19: what is the evidence for cloth masks? BMJ. 2020 Apr 7;369:m1422.Полный текст  Аннотация

348. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2020 Nov 18 [Epub ahead of print].Полный текст  Аннотация

349. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;(11):CD006207.Полный текст  Аннотация

350. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Полный текст  Аннотация

351. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Полный текст  Аннотация

352. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Полный текст  Аннотация

353. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Полный текст  Аннотация

354. Centers for Disease Control and Prevention. Serious adverse health events associated with methanol-based hand sanitizers. 2020 [internet publication].Полный текст

355. Mahmood A, Eqan M, Pervez S, et al. COVID-19 and frequent use of hand sanitizers; human health and environmental hazards by exposure pathways. Sci Total Environ. 2020 Jun 27;742:140561.Полный текст  Аннотация

356. Burns J, Movsisyan A, Stratil JM, et al. Travel‐related control measures to contain the COVID‐19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020 Sep 16:CD013717.Полный текст

357. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS‐CoV‐2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15:CD013718.Полный текст

358. Dollard P, Griffin I, Berro A, et al. Risk assessment and management of COVID-19 among travelers arriving at designated U.S. airports, January 17-September 13, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1681-5.Полный текст  Аннотация

359. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 14:CD013574.Полный текст

360. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Полный текст  Аннотация

361. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Полный текст  Аннотация

362. Centre for Evidence-Based Medicine; Mahtani KR, Heneghan C, Aronson JK. What is the evidence for social distancing during global pandemics? 2020 [internet publication].Полный текст

363. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis. 2020 Jun;20(6):631-3.Полный текст  Аннотация

364. Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis. 2020 Jun;20(6):678-88.Полный текст  Аннотация

365. Bavli I, Sutton B, Galea S. Harms of public health interventions against covid-19 must not be ignored. BMJ. 2020 Nov 2;371:m4074.Полный текст  Аннотация

366. Chu IY, Alam P, Larson H, et al. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J Travel Med. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

367. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2020 [internet publication].Полный текст

368. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19 [Epub ahead of print].Полный текст

369. Mahase E. Covid-19: what do we know so far about a vaccine? BMJ. 2020 Apr 27;369:m1679.Полный текст

370. Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020 Nov;8(11):e85-6.Полный текст  Аннотация

371. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-97.Полный текст  Аннотация

372. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 Apr 23;:1-20.Полный текст  Аннотация

373. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Jun;20(6):347-8.Полный текст  Аннотация

374. Callaway E. Coronavirus vaccine trials have delivered their first results - but their promise is still unclear. Nature. 2020 May;581(7809):363-4.Полный текст  Аннотация

375. Doshi P. Will covid-19 vaccines save lives? Current trials aren't designed to tell us. BMJ. 2020 Oct 21;371:m4037.Полный текст  Аннотация

376. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 Oct;586(7830):589-93.Полный текст  Аннотация

377. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020 Oct 14 [Epub ahead of print].Полный текст  Аннотация

378. Mahase E. Covid-19: Pfizer and BioNTech submit vaccine for US authorisation. BMJ. 2020 Nov 20;371:m4552.Полный текст  Аннотация

379. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med. 2020 Nov 12;383(20):1920-31.Полный текст  Аннотация

380. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020 Sep 29 [Epub ahead of print].Полный текст  Аннотация

381. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020 May 13 [Epub ahead of print].Полный текст  Аннотация

382. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Jul 20;:.Полный текст  Аннотация

383. AstraZeneca. Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause. 2020 [internet publication].Полный текст

384. AstraZeneca. COVID-19 vaccine AZD1222 clinical trials resumed in the UK. 2020 [internet publication].Полный текст

385. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020 Nov 18 [Epub ahead of print].Полный текст  Аннотация

386. University of Oxford. Oxford University breakthrough on global COVID-19 vaccine. 2020 [internet publication].Полный текст

387. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81.Полный текст  Аннотация

388. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020 Sep 8;324(10):951-60.Полный текст  Аннотация

389. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020 Nov 17 [Epub ahead of print].Полный текст

390. Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. 2020 Sep 2 [Epub ahead of print].Полный текст  Аннотация

391. Johnson & Johnson. Johnson & Johnson temporarily pauses all dosing in our Janssen COVID-19 vaccine candidate Clinical Trials. 2020 [internet publication].Полный текст

392. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-54.Полный текст  Аннотация

393. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479-88.Полный текст  Аннотация

394. US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. 2020 [internet publication].Полный текст

395. World Health Organization. "Immunity passports" in the context of COVID-19: scientific brief. 2020 [internet publication].Полный текст

396. Kofler N, Baylis F. Ten reasons why immunity passports are a bad idea. Nature. 2020 May;581(7809):379-81.Полный текст  Аннотация

397. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020 Aug 24;22(9):1653-6.Полный текст  Аннотация

398. Department of Health and Social Care. Everyone in the United Kingdom with symptoms now eligible for coronavirus tests. 2020 [internet publication].Полный текст

399. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020 Jul 7;(7):CD013665.Полный текст  Аннотация

400. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Полный текст

401. Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020 Jul;179(7):1029-46.Полный текст  Аннотация

402. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Полный текст

403. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Полный текст

404. Yang BY, Barnard LM, Emert JM, et al. Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) receiving emergency medical services in King County, Washington. JAMA Netw Open. 2020 Jul 1;3(7):e2014549.Полный текст  Аннотация

405. Centers for Disease Control and Prevention. Ten clinical tips on COVID-19 for healthcare providers involved in patient care. 2020 [internet publication].Полный текст

406. Sommer P, Lukovic E, Fagley E, et al. Initial clinical impressions of the critical care of COVID-19 patients in Seattle, New York City, and Chicago. Anesth Analg. 2020 Jul;131(1):55-60.Полный текст  Аннотация

407. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-4.Полный текст  Аннотация

408. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020 Sep;288(3):335-44.Полный текст  Аннотация

409. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Clin Infect Dis. 2020 Jun 23 [Epub ahead of print].Полный текст  Аннотация

410. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Полный текст  Аннотация

411. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Полный текст  Аннотация

412. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2020 May 5 [Epub ahead of print].Полный текст  Аннотация

413. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Полный текст  Аннотация

414. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Полный текст  Аннотация

415. Davis B, Rothrock AN, Swetland S, et al. Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis. J Am Coll Emerg Physicians Open. 2020 Jun 19;1(4):533-48.Полный текст  Аннотация

416. Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):266-75.Полный текст  Аннотация

417. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Jul 22 [Epub ahead of print].Полный текст  Аннотация

418. Gayam V, Konala VM, Naramala S, et al. Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. J Med Virol. 2020 May 25 [Epub ahead of print].Полный текст  Аннотация

419. Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020 Mar 20 [Epub ahead of print].Полный текст  Аннотация

420. Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020 May 16;395(10236):e84.Полный текст  Аннотация

421. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol. 2020 Aug 6 [Epub ahead of print].Полный текст  Аннотация

422. Li Y, Wang H, Wang F, et al. Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. Int J Infect Dis. 2020 Jun 11;98:80-3.Полный текст  Аннотация

423. Cook J, Harman K, Zoica B, et al. Horizontal transmission of severe acute respiratory syndrome coronavirus 2 to a premature infant: multiple organ injury and association with markers of inflammation. Lancet Child Adolesc Health. 2020 Jul;4(7):548-51.Полный текст  Аннотация

424. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020 Sep 1;174(9):868-73.Полный текст  Аннотация

425. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2020 Sep 10 [Epub ahead of print].Полный текст  Аннотация

426. Karabay M, Çınar N, Karakaya Suzan Ö, et al. Clinical characteristics of confirmed COVID-19 in newborns: a systematic review. J Matern Fetal Neonatal Med. 2020 Nov 19:1-12.Полный текст  Аннотация

427. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Аннотация

428. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Полный текст  Аннотация

429. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Полный текст  Аннотация

430. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Полный текст  Аннотация

431. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Полный текст  Аннотация

432. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Полный текст  Аннотация

433. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Полный текст

434. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Полный текст  Аннотация

435. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Полный текст  Аннотация

436. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Полный текст  Аннотация

437. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Полный текст  Аннотация

438. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Полный текст  Аннотация

439. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Полный текст  Аннотация

440. Public Health England. COVID-19: investigation and initial clinical management of possible cases. 2020 [internet publication].Полный текст

441. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2020 [internet publication].Полный текст

442. American Academy of Pediatrics. COVID-19 testing guidance. 2020 [internet publication].Полный текст

443. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020 Jul;81(1):e45-50.Полный текст  Аннотация

444. Williams E, Bond K, Zhang B, et al. Saliva as a noninvasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020 Jul 23;58(8):e00776.Полный текст  Аннотация

445. Caulley L, Corsten M, Eapen L, et al. Salivary detection of COVID-19. Ann Intern Med. 2020 Aug 28 [Epub ahead of print].Полный текст  Аннотация

446. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020 Sep 24;383(13):1283-6.Полный текст  Аннотация

447. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19. 2020 [internet publication].Полный текст

448. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2020 Jun 11 [Epub ahead of print].Полный текст  Аннотация

449. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Oct 1 [Epub ahead of print].Полный текст  Аннотация

450. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020 Mar 11;26(6).Полный текст  Аннотация

451. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020 Oct 1 [Epub ahead of print].Полный текст  Аннотация

452. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Полный текст

453. Jefferson T, Spencer E, Brassey J, et al; medRxiv. Viral cultures for COVID-19 infectivity assessment: systematic review. 2020 [internet publication].Полный текст

454. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Полный текст  Аннотация

455. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 May 22 [Epub ahead of print].Полный текст

456. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Полный текст  Аннотация

457. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Sep 29 [Epub ahead of print].Полный текст  Аннотация

458. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Полный текст  Аннотация

459. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Полный текст

460. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2020 [internet publication].Полный текст

461. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Полный текст

462. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Полный текст

463. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Полный текст  Аннотация

464. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Полный текст  Аннотация

465. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2020 [internet publication].Полный текст

466. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Полный текст

467. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Полный текст  Аннотация

468. Qu J, Wu C, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Apr 27 [Epub ahead of print].Полный текст  Аннотация

469. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Полный текст  Аннотация

470. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Полный текст

471. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Полный текст  Аннотация

472. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance. 2020 [internet publication].Полный текст

473. US Food and Drug Administration. Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2020 [internet publication].Полный текст

474. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. 2020 [internet publication].Полный текст

475. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020 Feb 6:200274.Полный текст  Аннотация

476. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Полный текст

477. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Полный текст  Аннотация

478. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Полный текст

479. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Полный текст  Аннотация

480. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Feb 27 [Epub ahead of print]. Аннотация

481. Tsikala Vafea M, Atalla E, Kalligeros M, et al. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. Clin Radiol. 2020 Nov;75(11):876.e33-9.Полный текст  Аннотация

482. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Полный текст  Аннотация

483. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Полный текст  Аннотация

484. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Полный текст  Аннотация

485. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Полный текст  Аннотация

486. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Полный текст  Аннотация

487. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Полный текст  Аннотация

488. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Jul 21 [Epub ahead of print].Полный текст  Аннотация

489. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Полный текст  Аннотация

490. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Полный текст  Аннотация

491. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Полный текст  Аннотация

492. Mohamed MFH, Al-Shokri S, Yousaf Z, et al. Frequency of abnormalities detected by point-of-care lung ultrasound in symptomatic COVID-19 patients: systematic review and meta-analysis. Am J Trop Med Hyg. 2020 Aug;103(2):815-21.Полный текст  Аннотация

493. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Полный текст  Аннотация

494. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Полный текст  Аннотация

495. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Полный текст  Аннотация

496. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Полный текст  Аннотация

497. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Полный текст  Аннотация

498. Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 2;146(8):729-32.Полный текст  Аннотация

499. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2020 Nov 13 [Epub ahead of print].Полный текст  Аннотация

500. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Oct 5 [Epub ahead of print].Полный текст

501. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Полный текст  Аннотация

502. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for coronavirus infection? A prospective case-control study from the United States. Gastroenterology. 2020 Sep;159(3):1161-3.Полный текст  Аннотация

503. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Полный текст  Аннотация

504. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Полный текст  Аннотация

505. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020 Jun 4;382(23):2268-70.Полный текст  Аннотация

506. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091.Полный текст  Аннотация

507. Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2020 Oct 2 [Epub ahead of print].Полный текст  Аннотация

508. National Institute for Health Research. Brain and nerve complications are more common than expected in younger patients with severe COVID-19. 2020 [internet publication].Полный текст

509. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82.Полный текст  Аннотация

510. Aggarwal K, Agarwal A, Jaiswal N, et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One. 2020 Nov 5;15(11):e0241661.Полный текст  Аннотация

511. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Полный текст  Аннотация

512. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Oct 1;138(10):1079-86.Полный текст  Аннотация

513. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Sep 16 [Epub ahead of print].Полный текст  Аннотация

514. Bataille V, Visconti A, Rossi R, et al; medRxiv. Diagnostic value of skin manifestation of SARS-CoV-2 infection. 2020 [internet publication].Полный текст

515. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Полный текст  Аннотация

516. Centers for Disease Control and Prevention. CDC’s diagnostic multiplex assay for flu and COVID-19 and supplies. 2020 [internet publication].Полный текст

517. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Полный текст  Аннотация

518. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Полный текст  Аннотация

519. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Полный текст  Аннотация

520. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Полный текст  Аннотация

521. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Полный текст  Аннотация

522. Liu J, Han P, Wu J, et al. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health. 2020 Sep;13(9):1224-8.Полный текст  Аннотация

523. Ceriello A. Hyperglycemia and the worse prognosis of COVID-19: why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract. 2020 Apr 29;163:108186.Полный текст  Аннотация

524. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020 May 9:1932296820924469.Полный текст  Аннотация

525. Iacobellis G, Penaherrera CA, Bermudez LE, et al. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res Clin Pract. 2020 May 1;164:108185.Полный текст  Аннотация

526. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

527. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Аннотация

528. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Полный текст  Аннотация

529. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Полный текст  Аннотация

530. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020 Jul;92(7):819-23.Полный текст  Аннотация

531. Aboughdir M, Kirwin T, Abdul Khader A, et al. Prognostic value of cardiovascular biomarkers in COVID-19: a review. Viruses. 2020 May 11;12(5).Полный текст  Аннотация

532. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 Jun;61(3):253-4.Полный текст  Аннотация

533. National Institute for Health and Care Excellence. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. 2020 [internet publication].Полный текст

534. Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med. 2020 Aug 18;173(4):304-5.Полный текст  Аннотация

535. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Полный текст  Аннотация

536. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Полный текст  Аннотация

537. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Полный текст  Аннотация

538. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Полный текст  Аннотация

539. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Полный текст  Аннотация

540. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Полный текст  Аннотация

541. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. 2020 [internet publication].Полный текст

542. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. 2020 [internet publication].Полный текст

543. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Полный текст

544. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Полный текст  Аннотация

545. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Полный текст  Аннотация

546. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Полный текст  Аннотация

547. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Полный текст  Аннотация

548. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Apr 22 [Epub ahead of print].Полный текст  Аннотация

549. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Полный текст  Аннотация

550. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Полный текст  Аннотация

551. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Полный текст  Аннотация

552. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Полный текст  Аннотация

553. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020 [internet publication].Полный текст

554. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Полный текст

555. World Health Organization. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. 2020 [internet publication].Полный текст

556. Arima Y, Shimada T, Suzuki M, et al. Severe acute respiratory syndrome coronavirus 2 infection among returnees to Japan from Wuhan, China, 2020. Emerg Infect Dis. 2020 Apr 10;26(7).Полный текст  Аннотация

557. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Полный текст  Аннотация

558. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Полный текст

559. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Oct 10 [Epub ahead of print].Полный текст  Аннотация

560. Chen G, Xie J, Dai G, et al; medRxiv. Validity of wrist and forehead temperature in temperature screening in the general population during the outbreak of 2019 novel coronavirus: a prospective real-world study. 2020 [internet publication].Полный текст

561. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2020 Oct 2 [Epub ahead of print].Полный текст  Аннотация

562. National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. 2020 [internet publication].Полный текст

563. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community. 2020 [internet publication].Полный текст

564. World Health Organization. Corticosteroids for COVID-19: living guidance. 2020 [internet publication].Полный текст

565. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Полный текст  Аннотация

566. Kilaru AS, Lee K, Snider CK, et al. Return hospital admissions among 1419 covid-19 patients discharged from five US emergency departments. Acad Emerg Med. 2020 Aug 27 [Epub ahead of print].Полный текст  Аннотация

567. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Jun 25 [Epub ahead of print].Полный текст  Аннотация

568. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Полный текст  Аннотация

569. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 Mar 30 [Epub ahead of print].Полный текст  Аннотация

570. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Полный текст  Аннотация

571. Centers for Disease Control and Prevention. Discontinuation of isolation for persons with COVID-19 not in healthcare settings. 2020 [internet publication].Полный текст

572. Public Health England. Guidance for stepdown of infection control precautions and discharging COVID-19 patients. 2020 [internet publication].Полный текст

573. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020 [internet publication].Полный текст

574. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. 2020 [internet publication].Полный текст

575. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020 Mar 27;368:m1185.Полный текст  Аннотация

576. Medicines and Healthcare products Regulatory Agency; Commission on Human Medicines. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19). 2020 [internet publication].Полный текст

577. World Health Organization. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19: scientific brief. 2020 [internet publication].Полный текст

578. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. 2020 [internet publication].Полный текст

579. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2020 Aug 18 [Epub ahead of print].Полный текст  Аннотация

580. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 May 20 [Epub ahead of print].Полный текст  Аннотация

581. Centers for Disease Control and Prevention. Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (interim guidance). 2020 [internet publication].Полный текст

582. NHS England. COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone. 2020 [internet publication].Полный текст

583. Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020 Jun 30 [Epub ahead of print].Полный текст  Аннотация

584. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Полный текст

585. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854-87.Полный текст  Аннотация

586. NHS England. Clinical guide for the optimal use of oxygen therapy during the coronavirus pandemic. 2020 [internet publication].Полный текст

587. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in novel coronavirus disease (COVID-19) patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Apr 21 [Epub ahead of print].Полный текст  Аннотация

588. Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic. Acad Emerg Med. 2020 May;27(5):375-8.Полный текст  Аннотация

589. Ng Z, Tay WC, Ho CHB. Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients. Eur Respir J. 2020 May 26 [Epub ahead of print].Полный текст  Аннотация

590. Golestani-Eraghi M, Mahmoodpoor A. Early application of prone position for management of Covid-19 patients. J Clin Anesth. 2020 May 26;66:109917.Полный текст  Аннотация

591. Thompson AE, Ranard BL, Wei Y, et al. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA Intern Med. 2020 Jun 17 [Epub ahead of print].Полный текст  Аннотация

592. Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med. 2020 Jun 19 [Epub ahead of print].Полный текст  Аннотация

593. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Полный текст  Аннотация

594. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Полный текст

595. Public Health England. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Полный текст

596. National Institute for Health and Care Excellence. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19. 2020 [internet publication].Полный текст

597. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 May 21 [Epub ahead of print].Полный текст  Аннотация

598. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Jun 2 [Epub ahead of print].Полный текст  Аннотация

599. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020 [internet publication].Полный текст

600. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Apr 15 [Epub ahead of print].Полный текст  Аннотация

601. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Полный текст  Аннотация

602. Wijaya I, Andhika R, Huang I. The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620960797.Полный текст  Аннотация

603. Flumignan RLG, de Sá Tinôco JD, Pascoal PIF, et al. Prophylactic anticoagulants for people hospitalised with COVID‐19. Cochrane Database Syst Rev. 2020 Oct 2:CD013739.Полный текст

604. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. J Am Coll Cardiol. 2020 Aug 24 [Epub ahead of print].Полный текст  Аннотация

605. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Полный текст  Аннотация

606. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Sep 2 [Epub ahead of print].Полный текст  Аннотация

607. Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Полный текст  Аннотация

608. Lamontagne F, Agoritsas T, Macdonald H, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2020 Nov 19;371:m4475.Полный текст  Аннотация

609. European Medicines Agency. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. 2020 [internet publication].Полный текст

610. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2020 [internet publication].Полный текст

611. Canelli R, Connor CW, Gonzalez M, et al. Barrier enclosure during endotracheal intubation. N Engl J Med. 2020 May 14;382(20):1957-8.Полный текст  Аннотация

612. Matava CT, Yu J, Denning S. Clear plastic drapes may be effective at limiting aerosolization and droplet spray during extubation: implications for COVID-19. Can J Anaesth. 2020 Apr 3 [Epub ahead of print].Полный текст  Аннотация

613. Lucchini A, Giani M, Isgrò S, et al. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation. Intensive Crit Care Nurs. 2020 Apr 2:102859.Полный текст  Аннотация

614. Adir Y, Segol O, Kompaniets D, et al. Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy. Eur Respir J. 2020 Apr 20 [Epub ahead of print].Полный текст  Аннотация

615. McEnery T, Gough C, Costello RW. COVID-19: respiratory support outside the intensive care unit. Lancet Respir Med. 2020 Apr 9 [Epub ahead of print].Полный текст  Аннотация

616. NHS England. Guidance for the role and use of non-invasive respiratory support in adult patients with COVID19 (confirmed or suspected). 2020 [internet publication].Полный текст

617. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Полный текст  Аннотация

618. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 May 22 [Epub ahead of print].Полный текст  Аннотация

619. Thomas R, Lotfi T, Morgano GP, et al. Update alert 2: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

620. Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ. 2020 Mar 24;368:m1201.Полный текст  Аннотация

621. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020 Jun 6;395(10239):1763-70.Полный текст  Аннотация

622. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 Apr 22;323(20):2052-9.Полный текст  Аннотация

623. Docherty AB, Harrison EM, Green CA, et al; medRxiv. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. 2020 [internet publication].Полный текст

624. Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020 May 26 [Epub ahead of print].Полный текст  Аннотация

625. NHS England. Clinical guide for the management of critical care for adults with COVID-19 during the coronavirus pandemic. 2020 [internet publication].Полный текст

626. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Полный текст  Аннотация

627. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Полный текст  Аннотация

628. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Apr 14 [Epub ahead of print].Полный текст  Аннотация

629. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Apr 24 [Epub ahead of print].Полный текст  Аннотация

630. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 Apr 27 [Epub ahead of print].Полный текст  Аннотация

631. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Полный текст  Аннотация

632. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping ARDS in COVID-19 patients: consequences for ventilator management. Ann Am Thorac Soc. 2020 May 12 [Epub ahead of print].Полный текст  Аннотация

633. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Полный текст  Аннотация

634. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Apr 22 [Epub ahead of print].Полный текст  Аннотация

635. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Полный текст  Аннотация

636. Pan C, Chen L, Lu C, et al. Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study. Am J Respir Crit Care Med. 2020 May 15;201(10):1294-7.Полный текст  Аннотация

637. Sartini C, Tresoldi M, Scarpellini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA. 2020 May 15 [Epub ahead of print].Полный текст  Аннотация

638. Elharrar X, Trigui Y, Dols AM, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA. 2020 May 15 [Epub ahead of print].Полный текст  Аннотация

639. American Thoracic Society. Diagnosis and management of COVID-19 disease. 2020 [internet publication].Полный текст

640. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Полный текст  Аннотация

641. NHS England. Clinical guide for extra corporeal membrane oxygenation (ECMO) for respiratory failure in adults during the coronavirus pandemic. 2020 [internet publication].Полный текст

642. Schmidt M, Hajage D, Lebreton G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020 Aug 13 [Epub ahead of print].Полный текст  Аннотация

643. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020 Sep 25 [Epub ahead of print].Полный текст  Аннотация

644. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11 [Epub ahead of print].Полный текст  Аннотация

645. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Полный текст  Аннотация

646. Campbell KH, Tornatore JM, Lawrence KE, et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in Southern Connecticut. JAMA. 2020 May 26 [Epub ahead of print].Полный текст  Аннотация

647. Fassett MJ, Lurvey LD, Yasumura L, et al. Universal SARS-Cov-2 screening in women admitted for delivery in a large managed care organization. Am J Perinatol. 2020 Jul 3 [Epub ahead of print].Полный текст  Аннотация

648. Bianco A, Buckley AB, Overbey J, et al. Testing of patients and support persons for coronavirus disease 2019 (COVID-19) infection before scheduled deliveries. Obstet Gynecol. 2020 May 19 [Epub ahead of print].Полный текст  Аннотация

649. Sutton D, Fuchs K, D'Alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020 Apr 13 [Epub ahead of print].Полный текст  Аннотация

650. American College of Obstetricians and Gynecologists. Novel coronavirus 2019 (COVID-19). 2020 [internet publication].Полный текст

651. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Mar 3 [Epub ahead of print].Полный текст  Аннотация

652. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6. Аннотация

653. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2020 [internet publication].Полный текст

654. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2020 [internet publication].Полный текст

655. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2020 Oct 12 [Epub ahead of print].Полный текст  Аннотация

656. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Полный текст

657. Centers for Disease Control and Prevention. Evaluation and management considerations for neonates at risk for COVID-19. 2020 [internet publication].Полный текст

658. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): care for breastfeeding women. 2020 [internet publication].Полный текст

659. Kalil AC. Treating COVID-19: off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA Mar 24 [Epub ahead of print].Полный текст  Аннотация

660. Marzolini C, Battegay M, Sendi P, et al. Prescribing in COVID-19 patients: should we take into account inflammation? Br J Clin Pharmacol. 2020 Aug 20 [Epub ahead of print].Полный текст  Аннотация

661. World Health Organization. Therapeutics and COVID-19: living guideline. 2020 [internet publication].Полный текст

662. Pan H, Peto R, Karim QA, et al; medRxiv. Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results. 2020 [internet publication].Полный текст

663. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (version 1). Ann Intern Med. 2020 Oct 5 [Epub ahead of print].Полный текст  Аннотация

664. Wilt TJ, Kaka AS, MacDonald R, et al. Remdesivir for adults with COVID-19: a living systematic review for an American College of Physicians practice points. Ann Intern Med. 2020 Oct 5 [Epub ahead of print].Полный текст  Аннотация

665. European Medicines Agency. First COVID-19 treatment recommended for EU authorisation. 2020 [internet publication].Полный текст

666. European Medicines Agency. Update on remdesivir: EMA will evaluate new data from Solidarity trial. 2020 [internet publication].Полный текст

667. US Food and Drug Administration. FDA approves first treatment for COVID-19. 2020 [internet publication].Полный текст

668. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 2020. 2020 [internet publication].Полный текст

669. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020 Jun 15 [Epub ahead of print].Полный текст  Аннотация

670. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. 2020 [internet publication].Полный текст

671. Regeneron Pharmaceuticals, Inc. REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements. 2020 [internet publication].Полный текст

672. Mahase E. Covid-19: RECOVERY trial will evaluate "antiviral antibody cocktail". BMJ. 2020 Sep 15;370:m3584.Полный текст  Аннотация

673. Centre for Evidence-Based Medicine; Ferner RE, Aronson JK. Monoclonal antibodies directed against SARS-CoV-2: synthetic neutralizing antibodies, the REGN-COV2 antibody cocktail. 2020 [internet publication].Полный текст

674. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2020 Oct 28 [Epub ahead of print].Полный текст  Аннотация

675. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. 2020 [internet publication].Полный текст

676. Eli Lilly and Company. Lilly statement regarding NIH’s ACTIV-3 clinical trial. 2020 [internet publication].Полный текст

677. AstraZeneca. COVID-19 long-acting antiBody (LAAB) combination AZD7442 rapidly advances into phase III clinical trials. 2020 [internet publication].Полный текст

678. US Food and Drug Administration. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment, another achievement in administration’s fight against pandemic. 2020 [internet publication].Полный текст

679. Joyner MJ, Senefeld JW, Klassen SA, et al; medRxiv. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. 2020 [internet publication].Полный текст

680. Sarkar S, Soni KD, Khanna P. Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol. 2020 Aug 10 [Epub ahead of print].Полный текст  Аннотация

681. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020 Oct 22;371:m3939.Полный текст  Аннотация

682. Chai KL, Valk SJ, Piechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600.Полный текст  Аннотация

683. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. 2020 [internet publication].Полный текст

684. ClinicalTrials.gov. Adaptive COVID-19 treatment trial 2 (ACTT-2). 2020 [internet publication].Полный текст

685. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-71.Полный текст  Аннотация

686. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-83.Полный текст  Аннотация

687. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949.Полный текст  Аннотация

688. Chen Z, Hu J, Zhang Z, et al; medRxiv. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. 2020 [internet publication].Полный текст

689. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849.Полный текст  Аннотация

690. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020 May 27 [Epub ahead of print].Полный текст  Аннотация

691. Hernandez AV, Roman YM, Pasupuleti V, et al. Update alert 3: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Ann Intern Med. 2020 Oct 21 [Epub ahead of print].Полный текст  Аннотация

692. Ladapo JA, McKinnon JE, McCullough PA, et al; medRxiv. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. 2020 [internet publication].Полный текст

693. Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so used early, for Covid-19: a systematic review. New Microbes New Infect. 2020 Oct 5:100776.Полный текст  Аннотация

694. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. 2020 Sep 30 [Epub ahead of print].Полный текст  Аннотация

695. Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2020 Nov 24 [Epub ahead of print].Полный текст

696. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 Oct 8 [Epub ahead of print].Полный текст  Аннотация

697. Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020 Jun 16;141(24):e906-7.Полный текст  Аннотация

698. Kamp TJ, Hamdan MH, January CT. Chloroquine or hydroxychloroquine for COVID-19: is cardiotoxicity a concern? J Am Heart Assoc. 2020 May 28:e016887.Полный текст  Аннотация

699. Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020 May 1 [Epub ahead of print].Полный текст  Аннотация

700. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1 [Epub ahead of print].Полный текст  Аннотация

701. Nguyen LS, Dolladille C, Drici MD, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation. 2020 May 22 [Epub ahead of print].Полный текст  Аннотация

702. TLC. TLC receives Australian and Taiwan approval to initiate phase I clinical trial of TLC19 inhalable liposomal hydroxychloroquine for COVID-19. 2020 [internet publication].Полный текст

703. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3;323(15):1488-94.Полный текст  Аннотация

704. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 May 7;382(19):1787-99.Полный текст  Аннотация

705. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5 [Epub ahead of print].Полный текст  Аннотация

706. Beyls C, Martin N, Hermida A, et al. Lopinavir-ritonavir treatment for COVID-19 infection in intensive care unit: risk of bradycardia. Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798.Полный текст  Аннотация

707. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020 Mar 25;21(7).Полный текст  Аннотация

708. Xie Y, Cao S, Li Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020 Apr 10 [Epub ahead of print].Полный текст  Аннотация

709. Zhang J, Yang Y, Yang N, et al. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review. Ann Transl Med. 2020 May;8(10):625.Полный текст  Аннотация

710. Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020 Nov 5 [Epub ahead of print].Полный текст  Аннотация

711. Genentech. Genentech’s phase III EMPACTA study showed Actemra reduced the likelihood of needing mechanical ventilation in hospitalized patients with COVID-19 associated pneumonia. 2020 [internet publication].Полный текст

712. Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatol. 2020 Sep 9 [Epub ahead of print].Полный текст  Аннотация

713. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2020 Oct 20 [Epub ahead of print].Полный текст  Аннотация

714. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020 Oct 20 [Epub ahead of print].Полный текст  Аннотация

715. Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2020 Oct 20 [Epub ahead of print].Полный текст  Аннотация

716. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020 Oct 21 [Epub ahead of print].Полный текст  Аннотация

717. Medicines and Healthcare products Regulatory Agency. Publication of an interim position statement: tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults). 2020 [internet publication].Полный текст

718. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun;2(6):e325-31.Полный текст  Аннотация

719. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020 Jul;2(7):e393-400.Полный текст  Аннотация

720. Navarro-Millán I, Sattui SE, Lakhanpal A, et al. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheumatol. 2020 Jun 30 [Epub ahead of print].Полный текст  Аннотация

721. ClinicalTrials.gov. Anakinra for COVID-19 respiratory symptoms (ANACONDA). 2020 [internet publication].Полный текст

722. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Полный текст

723. De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e465-73.Полный текст  Аннотация

724. Temesgen Z, Assi M, Shweta FNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-control study. Mayo Clin Proc. 2020 Aug [Epub ahead of print].Полный текст

725. Temesgen Z, Assi M, Vergidis P, et al. First clinical use of lenzilumab to neutralize GM-CSF in patients with severe COVID-19 pneumonia. medRxiv. 2020 Jun 14 [Epub ahead of print].Полный текст  Аннотация

726. Mahase E. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community. BMJ. 2020 Oct 1;371:m3847.Полный текст  Аннотация

727. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Полный текст

728. Mesoblast Limited. Second interim analysis of clinical outcomes after 135 patients results in recommendation to continue remestemcel-L phase 3 trial in COVID-19 ARDS. 2020 [internet publication].Полный текст

729. Cheng LL, Guan WJ, Duan CY, et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial. JAMA Intern Med. 2020 Sep 10 [Epub ahead of print].Полный текст  Аннотация

730. Centre for Evidence-Based Medicine; Soliman R, Brassey J, Plüddemann A, et al. Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence. 2020 [internet publication].Полный текст

731. World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief. 2020 [internet publication].Полный текст

732. Department of Health and Social Care. COVID-19 treatments could be fast-tracked through new national clinical trial initiative. 2020 [internet publication].Полный текст

733. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4 [Epub ahead of print].Полный текст  Аннотация

734. ClinicalTrials.gov. Losartan for patients with COVID-19 requiring hospitalization. 2020 [internet publication].Полный текст

735. ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. 2020 [internet publication].Полный текст

736. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020 Nov 12 [Epub ahead of print].Полный текст  Аннотация

737. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-704.Полный текст  Аннотация

738. ClinicalTrials.gov. Interferon lambda for immediate antiviral therapy at diagnosis in COVID-19 (ILIAD). 2020 [internet publication].Полный текст

739. Eiger BioPharmaceuticals. Eiger BioPharmaceuticals announces positive results of investigator sponsored randomized controlled trial at University of Toronto with peginterferon lambda in outpatients with mild to moderate COVID-19. 2020 [internet publication].Полный текст

740. National Institutes of Health. NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins. 2020 [internet publication].Полный текст

741. University of Oxford. PRINCIPLE trial. 2020 [internet publication].Полный текст

742. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Полный текст  Аннотация

743. Momekov G, Momekova D; medRxiv. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. 2020 [internet publication].Полный текст

744. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Полный текст  Аннотация

745. Shrestha DB, Budhathoki P, Khadka S, et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020 Sep 24;17(1):141.Полный текст  Аннотация

746. Nuffield Department of Population Health. Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial. 2020 [internet publication].Полный текст

747. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Полный текст  Аннотация

748. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Полный текст

749. Baladia E, Pizarro AB, Ortiz-Muñoz L, et al. Vitamin C for COVID-19: a living systematic review. Medwave. 2020 Jul 28;20(6):e7978.Полный текст  Аннотация

750. Zhang J, Rao X, Li Y; Research Square. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. 2020 [internet publication].Полный текст

751. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Полный текст  Аннотация

752. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Полный текст  Аннотация

753. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Полный текст  Аннотация

754. ClinicalTrials.gov. Vitamin D on prevention and treatment of COVID-19 (COVITD-19). 2020 [internet publication].Полный текст

755. ClinicalTrials.gov. COVID-19 and vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients (CoVitTrial). 2020 [internet publication].Полный текст

756. Centre for Evidence-Based Medicine; Lee J, van Hecke O, Roberts N. Vitamin D: a rapid review of the evidence for treatment or prevention in COVID-19. 2020 [internet publication].Полный текст

757. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Полный текст  Аннотация

758. National Institute for Health and Care Excellence. COVID-19 rapid evidence summary: vitamin D for COVID-19. 2020 [internet publication].Полный текст

759. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: authors' reply. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):722-3.Полный текст  Аннотация

760. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020 Mar 15;16(10):1708-17.Полный текст  Аннотация

761. Sun CY, Sun YL, Li XM. The role of Chinese medicine in COVID-19 pneumonia: a systematic review and meta-analysis. Am J Emerg Med. 2020 Jul 8 [Epub ahead of print].Полный текст  Аннотация

762. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020 Nov 12 [Epub ahead of print].Полный текст  Аннотация

763. Harch PG. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res. Apr-Jun 2020;10(2):61-2. Аннотация

764. Thibodeaux K, Speyrer M, Raza A, et al. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020 May 1;29(sup5a):S4-8. Аннотация

765. ClinicalTrials.gov. Hyperbaric oxygen for COVID-19 patients. 2020 [internet publication].Полный текст

766. ClinicalTrials.gov. Safety and efficacy of hyperbaric oxygen for ARDS in patients with COVID-19 (COVID-19-HBO). 2020 [internet publication].Полный текст

767. Martel J, Ko YF, Young JD, et al. Could nasal nitric oxide help to mitigate the severity of COVID-19? Microbes Infect. 2020 May 6 [Epub ahead of print].Полный текст  Аннотация

768. ClinicalTrials.gov. Intravenous aviptadil for critical COVID-19 with respiratory failure (COVID-AIV). 2020 [internet publication].Полный текст

769. ClinicalTrials.gov. Inhaled aviptadil for the treatment of non-acute lung injury in COVID-19 (AVINALI). 2020 [internet publication].Полный текст

770. NeuroRx. NeuroRx submits request for emergency use authorization for RLF-100™ (aviptadil) in the treatment of patients with critical COVID-19 and respiratory failure who have exhausted approved therapy. 2020 [internet publication].Полный текст

771. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020 Aug 3;3(8):e2017708.Полный текст  Аннотация

772. Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals' interim analysis from ODYSSEY study shows tradipitant may accelerate clinical improvement in patients with COVID-19 pneumonia. 2020 [internet publication].Полный текст

773. ClinicalTrials.gov. ODYSSEY: a study to investigate the efficacy of tradipitant in treating severe or critical COVID-19 infection. 2020 [internet publication].Полный текст

774. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Полный текст  Аннотация

775. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Jul 31 [Epub ahead of print].Полный текст  Аннотация

776. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Полный текст  Аннотация

777. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur J Clin Invest. 2020 Oct 7:e13421.Полный текст  Аннотация

778. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. Int J Infect Dis. 2020 Sep 29 [Epub ahead of print].Полный текст  Аннотация

779. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Полный текст  Аннотация

780. Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2020 Oct 24 [Epub ahead of print].Полный текст  Аннотация

781. Department of Health and Social Care. UK Biobank COVID-19 antibody study: round 1 results. 2020 [internet publication].Полный текст

782. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. JAMA Intern Med. 2020 Nov 24 [Epub ahead of print].Полный текст  Аннотация

783. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020 Jun 5 [Epub ahead of print].Полный текст  Аннотация

784. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological updates. 2020 [internet publication].Полный текст

785. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Полный текст  Аннотация

786. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Полный текст  Аннотация

787. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Полный текст  Аннотация

788. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Полный текст  Аннотация

789. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Полный текст  Аннотация

790. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Полный текст

791. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Полный текст  Аннотация

792. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Полный текст

793. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Полный текст

794. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 Mar 23 [Epub ahead of print].Полный текст  Аннотация

795. Bilinski A, Emanuel EJ. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020 Oct 12 [Epub ahead of print].Полный текст  Аннотация

796. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Полный текст  Аннотация

797. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Полный текст  Аннотация

798. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Полный текст  Аннотация

799. Lim ZJ, Subramaniam A, Reddy MP, et al. Case fatality rates for COVID-19 patients requiring invasive mechanical ventilation: a meta-analysis. Am J Respir Crit Care Med. 2020 Oct 29 [Epub ahead of print].Полный текст  Аннотация

800. Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission: United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1695-9.Полный текст  Аннотация

801. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Полный текст  Аннотация

802. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2020 Sep 8 [Epub ahead of print]. Аннотация

803. Parry J. Covid-19: Hong Kong scientists report first confirmed case of reinfection. BMJ. 2020 Aug 26;370:m3340.Полный текст  Аннотация

804. Gupta V, Bhoyar RC, Jain A, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. Clin Infect Dis. 2020 Sep 23 [Epub ahead of print].Полный текст  Аннотация

805. Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020 Sep 5 [Epub ahead of print].Полный текст  Аннотация

806. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al. A case of SARS-CoV-2 reinfection in Ecuador. Lancet Infect Dis. 2020 Nov 23 [Epub ahead of print].Полный текст

807. Larson D, Brodniak SL, Voegtly LJ, et al. A case of early re-infection with SARS-CoV-2. Clin Infect Dis. 2020 Sep 19 [Epub ahead of print].Полный текст  Аннотация

808. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020 Oct 12 [Epub ahead of print].Полный текст  Аннотация

809. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020 Sep 1 [Epub ahead of print].Полный текст  Аннотация

810. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 May 20 [Epub ahead of print].Полный текст  Аннотация

811. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020 May 11 [Epub ahead of print].Полный текст  Аннотация

812. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020 Jun 16;52(6):971-7.Полный текст  Аннотация

813. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. 2020 [internet publication].Полный текст

814. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. 2020 [internet publication]. bioRxiv. 2020 Nov 16 [Epub ahead of print].Полный текст

815. Lumley SF, O’Donnell D, Stoesser NE, et al; medRxiv. Antibodies to SARS-CoV-2 are associated with protection against reinfection. 2020 [internet publication].Полный текст

816. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Sep 11 [Epub ahead of print].Полный текст  Аннотация

817. Zuo J, Dowell A, Pearce H, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. bioRxiv. 2020 Nov 2 [Epub ahead of print].Полный текст

818. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020 Oct 28 [Epub ahead of print].Полный текст  Аннотация

819. Wajnberg A, Mansour M, Leven E, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020 Sep 25 [Epub ahead of print].Полный текст  Аннотация

820. Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020 Aug 18 [Epub ahead of print].Полный текст  Аннотация

821. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Jun 18 [Epub ahead of print].Полный текст  Аннотация

822. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Полный текст  Аннотация

823. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Nov 6 [Epub ahead of print].Полный текст  Аннотация

824. Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 Jul 9 [Epub ahead of print].Полный текст  Аннотация

825. Jiménez D, García-Sanchez A, Rali P, et al. Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis. Chest. 2020 Nov 17 [Epub ahead of print].Полный текст  Аннотация

826. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Полный текст  Аннотация

827. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Полный текст  Аннотация

828. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients With COVID-19 in a New York City health system. JAMA. 2020 Jul 20 [Epub ahead of print].Полный текст  Аннотация

829. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Полный текст

830. Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 May 11;7(6):e438-40.Полный текст  Аннотация

831. American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. 2020 [internet publication].Полный текст

832. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020 May 13;192:23-6.Полный текст  Аннотация

833. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020 May 6 [Epub ahead of print].Полный текст  Аннотация

834. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-3.Полный текст  Аннотация

835. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38.Полный текст  Аннотация

836. Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020 Jul 16;383(3):288-90.Полный текст  Аннотация

837. Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020 Aug;192:113-5.Полный текст  Аннотация

838. Xiao M, Zhang Y, Zhang S, et al. Brief report: anti-phospholipid antibodies in critically ill patients with coronavirus disease 2019 (COVID-19). Arthritis Rheumatol. 2020 Jun 30 [Epub ahead of print].Полный текст  Аннотация

839. Reyes Gil M, Barouqa M, Szymanski J, et al. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020 Aug 3;3(8):e2017539.Полный текст  Аннотация

840. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Полный текст  Аннотация

841. McGonagle D, O'Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020 Jul;2(7):e437-45.Полный текст  Аннотация

842. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Полный текст  Аннотация

843. Perini P, Nabulsi B, Massoni CB, et al. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet. 2020 May 16;395(10236):1546.Полный текст  Аннотация

844. Griffin DO, Jensen A, Khan M, et al. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Br J Haematol. 2020 Jul;190(1):e11-3.Полный текст  Аннотация

845. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14.Полный текст  Аннотация

846. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol. 2020 Jun;189(6):1053-4.Полный текст  Аннотация

847. Hemasian H, Ansari B. First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev Neurol (Paris). 2020 Jun;176(6):521-3.Полный текст  Аннотация

848. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Mar 27 [Epub ahead of print].Полный текст  Аннотация

849. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Полный текст  Аннотация

850. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 May 19;141(20):1648-55.Полный текст  Аннотация

851. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Полный текст  Аннотация

852. Prasitlumkum N, Chokesuwattanaskul R, Thongprayoon C, et al. Incidence of myocardial injury in COVID-19-infected patients: a systematic review and meta-analysis. Diseases. 2020 Oct 27;8(4):E40.Полный текст  Аннотация

853. Bansal A, Kumar A, Patel D, et al. Meta-analysis comparing outcomes in patients with and without cardiac injury and coronavirus disease 2019 (COVID 19). Am J Cardiol. 2020 Nov 17 [Epub ahead of print].Полный текст  Аннотация

854. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Полный текст  Аннотация

855. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Полный текст  Аннотация

856. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Полный текст  Аннотация

857. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Полный текст  Аннотация

858. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Полный текст  Аннотация

859. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Полный текст  Аннотация

860. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Полный текст  Аннотация

861. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25;5(7):802-10.Полный текст  Аннотация

862. He XW, Lai JS, Cheng J, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 15;48(0):E011. Аннотация

863. Santoso A, Pranata R, Wibowo A, et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020 Apr 19 [Epub ahead of print].Полный текст  Аннотация

864. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 May 14;41(19):1821-9.Полный текст  Аннотация

865. National Institute for Health and Care Excellence. COVID-19 rapid guideline: acute myocardial injury. 2020 [internet publication].Полный текст

866. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 May 5 [Epub ahead of print].Полный текст  Аннотация

867. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Полный текст  Аннотация

868. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 27 [Epub ahead of print].Полный текст  Аннотация

869. Lin L, Wang X, Ren J, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open. 2020 Nov 10;10(11):e042573.Полный текст  Аннотация

870. Stewart DJ, Hartley JC, Johnson M, et al. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health. 2020 Jun 15;4(8):e28-9.Полный текст  Аннотация

871. National Institute for Health and Care Excellence. COVID-19 rapid guideline: acute kidney injury in hospital. 2020 [internet publication].Полный текст

872. Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020 May 5 [Epub ahead of print].Полный текст  Аннотация

873. Nasr SH, Kopp JB. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int Rep. 2020 May 4;5(6):759-61.Полный текст  Аннотация

874. Gross O, Moerer O, Weber M, et al. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020 May 16;395(10236):e87-8.Полный текст  Аннотация

875. Kunutsor SK, Laukkanen JA. Hepatic manifestations and complications of COVID-19: a systematic review and meta-analysis. J Infect. 2020 Jun 21 [Epub ahead of print].Полный текст  Аннотация

876. Wijarnpreecha K, Ungprasert P, Panjawatanan P, et al. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2020 Jul 3 [Epub ahead of print]. Аннотация

877. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Полный текст  Аннотация

878. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Полный текст  Аннотация

879. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020 Oct 21 [Epub ahead of print].Полный текст  Аннотация

880. Panda PK, Sharawat IK, Panda P, et al. Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Sep 10 [Epub ahead of print].Полный текст  Аннотация

881. Restivo DA, Centonze D, Alesina A, et al. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020 Aug 10 [Epub ahead of print].Полный текст  Аннотация

882. Chua TH, Xu Z, King NKK. Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020 Oct 19:1-20. Аннотация

883. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Полный текст  Аннотация

884. Nannoni S, de Groot R, Bell S, et al. EXPRESS: stroke in COVID-19 – a systematic review and meta-analysis. Int J Stroke. 2020 Oct 26 [Epub ahead of print].Полный текст  Аннотация

885. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Полный текст  Аннотация

886. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Jul 9 [Epub ahead of print].Полный текст  Аннотация

887. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Полный текст  Аннотация

888. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2020 Aug 25 [Epub ahead of print].Полный текст  Аннотация

889. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. 2020 Nov 1;106349.Полный текст  Аннотация

890. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug;25:100484.Полный текст  Аннотация

891. COVID Symptom Study. How long does COVID-19 last? 2020 [internet publication].Полный текст

892. Mahase E. Covid-19: what do we know about “long covid”? BMJ. 2020 Jul 14;370:m2815.Полный текст  Аннотация

893. NHS England. National guidance for post-COVID syndrome assessment clinics. 2020 [internet publication].Полный текст

894. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network: United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8.Полный текст  Аннотация

895. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Полный текст  Аннотация

896. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020 Nov 11 [Epub ahead of print].Полный текст  Аннотация

897. Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020 Nov 10 [Epub ahead of print].Полный текст  Аннотация

898. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2020 Nov 17 [Epub ahead of print].Полный текст  Аннотация

899. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Полный текст  Аннотация

900. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13:101623.Полный текст  Аннотация

901. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Полный текст  Аннотация

902. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-7.Полный текст  Аннотация

903. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Полный текст  Аннотация

904. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Полный текст  Аннотация

905. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `'cytokine storm' in COVID-19. J Infect. 2020 Jun;80(6):607-13.Полный текст  Аннотация

906. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16 [Epub ahead of print].Полный текст  Аннотация

907. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020 Apr 28 [Epub ahead of print].Полный текст  Аннотация

908. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020 May 1;130(5):2202-5.Полный текст  Аннотация

909. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020 Oct 16 [Epub ahead of print].Полный текст  Аннотация

910. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020 Mar 25:108393.Полный текст  Аннотация

911. Pain CE, Felsenstein S, Cleary G, et al. Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatol. 2020 May 15;2(7):e376-9.Полный текст  Аннотация

912. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: a systematic review. J Pediatr. 2020 Aug 5 [Epub ahead of print].Полный текст  Аннотация

913. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19–associated multisystem inflammatory syndrome in children: United States, March–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-80.Полный текст  Аннотация

914. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020 Aug 17 [Epub ahead of print].Полный текст  Аннотация

915. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [internet publication].Полный текст

916. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 [internet publication].Полный текст

917. Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2020 Nov 14 [Epub ahead of print].Полный текст  Аннотация

918. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2020 Aug 11 [Epub ahead of print].Полный текст  Аннотация

919. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020 Jul 9 [Epub ahead of print].Полный текст  Аннотация

920. Valverde I, Singh Y, Sanchez-de-Toledo J, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2020 Nov 9 [Epub ahead of print].Полный текст  Аннотация

921. Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020 Sep 18 [Epub ahead of print].Полный текст  Аннотация

922. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. 2020 Jul 23 [Epub ahead of print].Полный текст  Аннотация

923. Shulman ST. Pediatric coronavirus disease-2019-associated multisystem inflammatory syndrome. J Pediatric Infect Dis Soc. 2020 Jul 13;9(3):285-6.Полный текст  Аннотация

924. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020 Aug 18 [Epub ahead of print].Полный текст  Аннотация

925. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection: United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 9 [Epub ahead of print].Полный текст  Аннотация

926. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2020 Aug 28 [Epub ahead of print].Полный текст  Аннотация

927. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun;63(6):528-34.Полный текст  Аннотация

928. Blaize M, Mayaux J, Nabet C, et al. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis. 2020 Apr 28;26(7).Полный текст  Аннотация

929. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al. COVID-19 associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020 May 12 [Epub ahead of print].Полный текст  Аннотация

930. Alanio A, Dellière S, Fodil S, et al. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020 Jun;8(6):e48-9.Полный текст  Аннотация

931. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Полный текст  Аннотация

932. Verweij PE, Gangneux JP, Bassetti M, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020 Jun;1(2):e53-5.Полный текст  Аннотация

933. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Полный текст  Аннотация

934. Bruno G, Fabrizio C, Santoro CR, et al. Pancreatic injury in the course of coronavirus disease 2019: a not-so-rare occurrence. J Med Virol. 2020 Jun 4 [Epub ahead of print].Полный текст  Аннотация

935. McNabb-Baltar J, Jin DX, Grover AS, et al. Lipase elevation in patients with COVID-19. Am J Gastroenterol. 2020 Jun 3 [Epub ahead of print].Полный текст  Аннотация

936. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2020 Jun 3 [Epub ahead of print].Полный текст  Аннотация

937. Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020 Jul;190(1):29-31.Полный текст  Аннотация

938. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Полный текст  Аннотация

939. Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020 Jul 30 [Epub ahead of print].Полный текст  Аннотация

940. Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa276.Полный текст  Аннотация

941. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24 [Epub ahead of print].Полный текст  Аннотация

942. Centre for Evidence-Based Medicine; Greenhalgh T, Treadwell J, Burrow R, et al. NEWS (or NEWS2) score when assessing possible COVID-19 patients in primary care? 2020 [internet publication].Полный текст

943. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Aug 24 [Epub ahead of print].Полный текст  Аннотация

944. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Jul 16 [Epub ahead of print].Полный текст  Аннотация

945. Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020 May 1;48(8):e657-65.Полный текст  Аннотация

946. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020 Apr 9 [Epub ahead of print].Полный текст  Аннотация

947. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 May 12 [Epub ahead of print].Полный текст  Аннотация

948. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open. 2020 Sep 25;10(9):e040729.Полный текст  Аннотация

949. Yadaw AS, Li YC, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health. 2020 Oct;2(10):e516-25.Полный текст  Аннотация

950. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020 Sep 9;370:m3339.Полный текст  Аннотация

951. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020 Oct 20;371:m3731.Полный текст  Аннотация

952. Centers for Disease Control and Prevention. Interim guidance for public health professionals managing people with COVID-19 in home care and isolation who have pets or other animals. 2020 [internet publication].Полный текст

953. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): COVID-19 and animals. 2020 [internet publication].Полный текст

954. Shi J, Wen Z, Zhong G, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020 May 29;368(6494):1016-20.Полный текст  Аннотация

955. IDEXX Laboratories. Leading veterinary diagnostic company sees no COVID-19 cases in pets. 2020 [internet publication].Полный текст

956. Newman A, Smith D, Ghai RR, et al. First reported cases of SARS-CoV-2 infection in companion animals: New York, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):710-3.Полный текст  Аннотация

957. Halfmann PJ, Hatta M, Chiba S, et al. Transmission of SARS-CoV-2 in domestic cats. N Engl J Med. 2020 Aug 6 [Epub ahead of print].Полный текст  Аннотация

958. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): if you have pets. 2020 [internet publication].Полный текст

959. Phelan D, Kim JH, Chung EH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. JAMA Cardiol. 2020 May 13 [Epub ahead of print].Полный текст  Аннотация

960. American Academy of Pediatrics. COVID-19 interim guidance: return to sports. 2020 [internet publication].Полный текст